Formic Acid

Formic Acid

SCHEMBL4748418

CS(=O)(=O)Oc1cccc(CC(NC2=NCCN2)c2ccccc2)c1.O=CO

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 1/20 0.38
▸ ITGB3 P05106 2/20 0.35
▸ ITGAV P06756 2/20 0.35
▸ MAOA P21397 1/20 0.35
▸ MAOB P27338 1/20 0.35
▸ ITGA2B P08514 1/20 0.35
▸ WDR5 P61964 4/20 0.35
▸ HTR1B P28222 1/20 0.35
▸ ADRB3 P13945 4/20 0.34
▸ ADRB2 P07550 3/20 0.34
▸ ADRB1 P08588 1/20 0.34
▸ PPARG P37231 1/20 0.34
▸ PPARA Q07869 1/20 0.34
▸ SLC6A2 P23975 1/20 0.34
▸ SLC6A4 P31645 1/20 0.34
▸ CRHBP P24387 1/20 0.33
▸ CRHR2 Q13324 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4788381 0.95 FAAH (0.39) FAAHITGB3ITGAVMAOAMAOB
SCHEMBL4787543 0.85 ADRA2A (0.39) ITGB3ITGAVMAOAMAOBITGA2B
Acetic Acid SCHEMBL4915061 0.83 ITGB3 (0.39) ITGB3ITGAVMAOAMAOBITGA2B
Formic Acid SCHEMBL4748746 0.82 NISCH (0.38) ITGB3ITGAVITGA2BWDR5SLC6A2
SCHEMBL4748639 0.77 BCHE (0.46) ITGB3ITGAVMAOAMAOBITGA2B
SCHEMBL4786568 0.77 HTR1B (0.49) MAOAMAOBWDR5HTR1BSLC6A2
SCHEMBL949042 0.76 KDM4E (0.52) MAOAMAOB
Iodide SCHEMBL951481 0.75 KDM4E (0.51) MAOAMAOB
SCHEMBL14042569 0.75 HTR1B (0.46) ITGB3ITGAVMAOAMAOBITGA2B
SCHEMBL14042330 0.75 SLC6A2 (0.46) MAOAMAOBWDR5SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008123821-A1 4, 5-DIHYDRO-LH-IMIDAZOL-2-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF RESPIRATORY, CARDIOVASCULAR, NEUROLOGICAL OR GASTROINTESTINAL DISORDERS ALBIREO AB (SE) 2008-10-16 — — WO disclosed
Send feedback